Best peptides for sexual health, ranked by trial data.

Sexual health is the peptide category where consumer copy and published evidence diverge the most. When you search the best peptides for sexual health, the honest shortlist is short. Even the one FDA-approved option comes with caveats nobody puts in the marketing.

We've watched this category for years. Evidence quality and marketing volume run in opposite directions here. PT-141 (Bremelanotide), sold as the FDA-approved Vyleesi, has the only Phase III randomized-controlled-trial base. And the most rigorous re-analyses of that trial data, by Spielmans and colleagues, are uncomfortable reading.

They found that 72.7% of protocol-listed outcomes weren't reported in the principal publication. The patient-preference signal in the open-label extension was striking. Effect sizes ranged from "nil to small" (Spielmans, 2021).

Melanotan II marketing has the opposite shape: loud claims, no controlled trials, and documented melanoma case reports in the dermatology literature.

We've ranked the five peptides most-promoted for sexual health by depth of published evidence. We've surfaced the trial caveats consumer marketing typically omits. And we've framed each against standard-of-care comparators so you can put the peptide claim in context.

How peptides support sexual function

Before we rank the peptides, here's how they actually work. The sexual-health peptide mechanisms fall into three buckets.

Central melanocortin agonism is the PT-141 and Melanotan II story. MC3R and MC4R (melanocortin receptors in the brain) activate in the medial preoptic area of the hypothalamus. That drives dopamine signaling tied to sexual desire. This is mechanistically distinct from PDE5 inhibitors like sildenafil or tadalafil, which work peripherally by relaxing blood vessels.

HPG-axis modulation is the Kisspeptin story. Kisspeptin neurons drive GnRH (gonadotropin-releasing hormone) release, which controls LH and FSH, which controls testosterone and estrogen production. Kisspeptin sits upstream of the entire sex-hormone cascade.

Indirect mechanisms cover everything else. Tesamorelin's libido effects are inferred from its broader effects on the growth hormone and IGF-1 axis. BPC-157's anecdotal libido reports lack a defined receptor mechanism in this context.

The five, side by side on the published evidence, before we take each in turn.

1. PT-141 (Bremelanotide): the FDA-approved option, with caveats

Bremelanotide (PT-141) is a synthetic cyclic 7-amino-acid melanocortin-receptor agonist. Its main therapeutic activity is at MC4R, one of the brain receptors that drive sexual desire. It's a metabolite of Melanotan II that Palatin Technologies developed deliberately into a sexual-desire therapy.

It's FDA-approved as Vyleesi (June 2019) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The label calls for subcutaneous autoinjector use roughly 45 minutes before anticipated sexual activity.

The Phase III RECONNECT program (RECONNECT 301 and 302) enrolled 1,247 premenopausal women with HSDD across two identically designed 24-week placebo-controlled trials. Primary efficacy outcomes (FSFI desire domain and FSDS-DAO Item 13) showed statistically significant improvements with bremelanotide vs. placebo (Simon et al., 2022).

The re-analyses are where it gets uncomfortable for you as a reader trying to decide whether the data supports the marketing. Spielmans and Ellefson's work found 72.7% of protocol-listed outcomes weren't reported in the principal publication. Adverse-event-induced discontinuation was substantially higher on bremelanotide (OR 11.98, NNH 6). More participants on placebo than on bremelanotide elected to continue into the open-label extension (Spielmans, 2021).

A 2023 follow-up examined 11 ClinicalTrials.gov-specified outcomes (8 previously unpublished) and found effect sizes "from nil to small" (Spielmans & Ellefson, 2023).

The safety profile from pooled Phase 1–3 data across 3,500 subjects in 43 studies: nausea rate 40.0% (vs 1.3% on placebo). Flushing 20.3%. Headache 11.3%. Injection-site reactions 5.4%. Transient blood-pressure increases on ambulatory monitoring. Focal hyperpigmentation in over one-third of subjects after up to 16 consecutive daily doses (Clayton et al., 2022).

• Typical approved use: subcutaneous autoinjector, 1.75 mg, ~45 min before anticipated sexual activity. Max one dose per 24 hours, max eight doses per month.
• Regulatory status: FDA-approved 2019 (Vyleesi) for premenopausal HSDD in women. The Phase III male program was discontinued.
• WADA status: Not explicitly listed.

Strengths. Only Phase III RCT-grade evidence in the sexual-health peptide category. FDA approval establishes a safety floor. Mechanistically distinct from PDE5 inhibitors, which means it can work for people who don't respond to sildenafil.

Limitations. The 40% nausea rate is the dominant tolerability issue. Spielmans re-analyses showed selective outcome reporting and modest effect sizes. Hyperpigmentation builds up with repeated dosing. Off-label male use is empirical, not Phase III-validated.

PT-141

Melanocortin Agonist

Cyclic heptapeptide 7 aa Melanocortin agonist

The same compound as FDA-approved Vyleesi, cited across the RECONNECT Phase III program. Lab-verified identity and purity.

Shop PT-141

2. Tesamorelin: FDA-approved GHRH analog with off-label libido reports

Tesamorelin is a 44-amino-acid stabilized GHRH (growth hormone-releasing hormone) analog. We'll be brief here because the sexual-health evidence is thin. It carries an N-terminal trans-3-hexenoyl modification that protects it from breakdown. It's the same molecule as FDA-approved Egrifta (2010) for HIV-associated lipodystrophy.

The sexual-health relevance is off-label and indirect. Anecdotal libido improvement reports come from users on Tesamorelin for body-composition indications. The mechanism story: restoring more youthful pulsatile growth hormone and downstream IGF-1 may contribute to libido through broader HPA-axis effects.

There's no Phase III sexual-health RCT for Tesamorelin. The libido evidence is anecdotal and secondary in trials run for other indications. The FDA approval for HIV-lipodystrophy and the long safety follow-up in that population establish the regulatory floor.

• Typical research protocol: subcutaneous, daily dosing in the Egrifta protocol.
• Regulatory status: FDA-approved (Egrifta, Egrifta SV) for HIV-lipodystrophy. Sexual-health use is fully off-label.
• WADA status: S2 Peptide Hormones — prohibited at all times.

Strengths. FDA approval establishes a safety baseline. Long-acting pharmacokinetics. Same molecule as approved Egrifta, so manufacturing pathways exist.

Limitations. No Phase III sexual-health trial. Libido effects are inferred from broader use. WADA-banned.

3. Melanotan II: the cautionary cousin of PT-141

Melanotan II is a synthetic cyclic heptapeptide analog of alpha-MSH. The University of Arizona developed it in the 1980s as a research tool to study melanocortin receptor pharmacology and skin pigmentation. It's the chemical parent of bremelanotide.

Here's the back-story most marketing skips. PT-141 was identified after researchers studying Melanotan II noted the sexual side effects, and the molecule was developed deliberately into a sexual-desire therapy. The reason PT-141 exists at all is that Melanotan II had unacceptable safety concerns.

Melanotan II has never been approved for any therapeutic indication anywhere. Despite that, it's one of the most widely diverted research peptides on the consumer grey market. Vendors sell it as a tanning agent ("Barbie drug") and a male sexual-enhancement product.

The published dermatology literature has documented serious adverse events from grey-market use. Renal infarction. Rhabdomyolysis. Melanocytic lesion changes that raised melanoma concerns in case reports from the British Journal of Dermatology and other dermatology journals.

• Documented adverse events: renal infarction, rhabdomyolysis, melanocytic lesion changes, atypical melanocyte hyperplasia.
• Regulatory status: Not approved anywhere globally. Not in the peptriva catalog.
• WADA status: Not explicitly listed; interpretation may apply.

Strengths. The mechanism case (melanocortin agonism for sexual function) is real. PT-141 is what captures that case inside a safer drug-development frame.

Limitations. Documented serious adverse events from grey-market use. Melanocytic lesion changes in published case reports. Never approved as a therapeutic. The right peptide here is the daughter compound (PT-141), not the parent.

4. Kisspeptin-10/54: HPG-axis modulation with Phase II RCT data

Kisspeptin-10 and Kisspeptin-54 are short peptide forms (10 and 54 residues) of the kisspeptin family. They're the hypothalamic neuropeptides that drive GnRH release and control the entire HPG (hypothalamic-pituitary-gonadal) axis.

The sexual-health relevance sits upstream of testosterone and estrogen production. Kisspeptin pulses drive LH and FSH, which drive the gonads to make sex hormones. Kisspeptin sits at the top of the cascade.

The published Kisspeptin trial literature is more substantial than most peptides on this list. Imperial College London and other groups have run Phase I and Phase II RCTs in healthy adults and clinical populations. They've shown LH and testosterone elevation after kisspeptin dosing. A 2023 RCT in men with HSDD showed Kisspeptin-54 produced effects on sexual brain activation in fMRI imaging.

The clinical translation is incomplete. No Phase III RCT on a sexual-function endpoint has run.

• Typical research protocol: IV infusion or subcutaneous bolus in published trials.
• Regulatory status: Not FDA-approved. Active research-development program.
• WADA status: Not explicitly listed; HPG-axis modulators are subject to interpretation.
• Not in the peptriva catalog.

Strengths. Defined upstream HPG-axis mechanism. Substantial Phase II RCT data. Reputable academic groups actively investigating.

Limitations. No Phase III on a sexual-function endpoint. Not yet a clinical product.

5. BPC-157: anecdotal libido reports, zero sexual-endpoint data

We're including BPC-157 here because anecdotal reports of libido and mood improvement appear consistently in users running BPC-157 for other reasons (tendon, gut, post-surgical recovery). The mechanism case is unclear. BPC-157's broader pleiotropic effects (vessel growth via VEGFR2, nitric-oxide synthesis, fibroblast recruitment) don't map cleanly onto a sexual-health receptor.

There's no published sexual-endpoint trial for BPC-157. The 2025 HSS Journal systematic review covered orthopaedic indications only. The 36-study literature base doesn't include sexual-function endpoints. The libido reports are entirely outside the published literature.

• Typical research protocol: subcutaneous at standard 250–500 mcg/day.
• Regulatory status: Not FDA-approved. FDA Cat 2 compounding restriction (2023). WADA S0 since January 2022.

Strengths. Well-tolerated in the broader literature. Adjacent benefits commonly reported.

Limitations. Zero sexual-endpoint data. Anecdotal reports only. WADA-prohibited.

Adjacent / support peptides

Kisspeptin-54 is covered above. The longer kisspeptin form has been more-studied in some indications. Oxytocin has been studied for partner-bonding effects in research contexts, with substantial but mixed or negative trial data on grey-market indications. HCG and hCG analogs are clinical fertility-treatment tools and out of scope for this review.

Optimal stacking protocols

There's no published stacking literature for sexual-health peptides. The empirical patterns in user communities pair PT-141 with PDE5 inhibitors like sildenafil or tadalafil. The logic is synergistic central-and-peripheral mechanism: PT-141 supplies the desire signal in the brain, sildenafil supplies peripheral vasodilation.

The combination is mechanistically coherent. It should be approached cautiously given PT-141's transient blood-pressure effect. Sildenafil and other PDE5 inhibitors have known cardiovascular contraindications.

A second pattern pairs Tesamorelin (long-acting GH-axis) with PT-141 (acute on-demand). The logic: Tesamorelin supports baseline HPA / IGF-1 axis; PT-141 supplies the acute melanocortin signal when needed. No trial has tested this combination.

Cycle length for sexual-health peptides runs shorter than other categories. PT-141 is dosed event-by-event, not chronically.

Lifestyle considerations

The largest-effect interventions for sexual function aren't peptide-based. If you only have time for one of these, start with cardiovascular health.

• Cardiovascular health. Blood pressure, lipids, and vascular health are the single largest physiological determinant of erectile function in men.
• Sleep. Both quality and duration modulate testosterone production.
• Exercise. Aerobic and resistance training have RCT-grade evidence for sexual function in both men and women.
• Mental health. Depression and anxiety are common contributors to sexual dysfunction with specific evidence-based treatments.
• Relationship factors. Often the largest single variable, and the one peptides can't touch.
• Medication review. SSRIs, beta-blockers, and several other commonly-prescribed drug classes have sexual-side-effect profiles that may be reversible with prescribing changes.

Peptide stacking sits on top of these foundations, not in place of them.

Tesamorelin

Stabilized GHRH

10 mg ≥99% pure Lyophilized

A 44-aa stabilized GHRH analog — the same molecule as FDA-approved Egrifta. The reference compound used across the cited GH-axis research. COA available with each lot.

Learn more

Safety, monitoring, and legal status

Three things to know. First. PT-141 / Vyleesi is the only FDA-approved sexual-health peptide on this list. The 2019 approval covers premenopausal HSDD in women specifically. Off-label male use is widespread, but the Phase III male development program was discontinued.

Second. Melanotan II has documented serious adverse events from grey-market use and isn't approved anywhere. We include it on this list to flag the cautions, not to recommend it.

Third. The WADA picture: PT-141 isn't explicitly listed. Tesamorelin is S2. BPC-157 is S0.

Here's what we'd bring to a clinician about PT-141 safety. The 40% nausea rate is the dominant tolerability issue. Transient blood-pressure elevation warrants caution in uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation hits over one-third of subjects with repeated daily dosing — relevant if you're using it more often than the label allows (max one dose per 24 hours, max 8 doses per month).

Questions worth bringing to your clinician:

• Have we evaluated cardiovascular risk factors? The largest single physiological determinant of male erectile function.
• What does my medication list look like? SSRIs, beta-blockers, and several other classes have sexual side effects that may be reversible.
• Is HSDD or low-libido the right diagnosis? Depression, thyroid dysfunction, and relationship factors can present the same way.
• What does the FDA label actually say? Vyleesi is for premenopausal HSDD in women. Other uses are off-label.
• What's the source and chain of custody? Grey-market PT-141 has been identified in adulterated performance-enhancing drug products (Mestria et al., 2021).

Frequently asked questions

Does PT-141 work for men? The Phase III male program was discontinued because efficacy didn't meet expectations. Off-label male use is widespread but lacks Phase III RCT validation.

Is Melanotan II safer than PT-141? The opposite. PT-141 was developed specifically because Melanotan II had unacceptable side-effect concerns, including documented melanocytic lesion changes.

Can PT-141 be used with sildenafil? The combination is documented in empirical use. PT-141 has a transient blood-pressure effect. Sildenafil has known cardiovascular contraindications. You'll want clinical supervision for the stack, not just the individual products.

How often can PT-141 be used? The FDA label is max one dose per 24 hours, max 8 doses per month. Off-label use exceeding this is what's tied to the hyperpigmentation case reports.